ATNM · Actinium Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $90.0K | - | $81.0K | $1.03M | $1.14M | - |
| Cost of Revenue | - | - | - | - | $900.0K | - |
| Gross Profit | - | - | - | - | $244.0K | - |
| R&D | $21.12M | $30.05M | $38.67M | $23.14M | $18.03M | $16.09M |
| SG&A | $15.21M | $12.08M | $13.33M | $12.00M | $8.08M | $6.31M |
| Total Operating Expenses | $36.34M | $42.12M | $52.00M | $35.13M | $26.11M | $22.39M |
| D&A | $197.0K | $197.0K | $790.0K | $699.0K | $524.0K | $447.0K |
| Operating Income | ($36.25M) | ($42.12M) | ($51.92M) | ($34.10M) | ($24.96M) | ($22.39M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($33.89M) | ($38.24M) | ($48.82M) | ($33.02M) | ($24.77M) | ($22.21M) |
| EPS - Basic | ($1.09) | ($1.27) | ($1.83) | ($1.20) | - | - |
| EPS - Diluted | ($1.09) | ($1.27) | ($1.83) | ($1.20) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $48.00M | $72.90M | $76.68M | $108.91M | $77.83M | $63.56M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $49.38M | $74.51M | $78.26M | $110.94M | $79.75M | $64.92M |
| Total Assets | $51.77M | $76.90M | $81.44M | $114.19M | $80.39M | $66.40M |
| Current Liabilities | $7.97M | $8.15M | $8.49M | $10.63M | $6.84M | $4.77M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $43.94M | $44.14M | $45.07M | $47.71M | $6.84M | $5.08M |
| Stockholders' Equity | $7.83M | $32.76M | $36.38M | $66.48M | $73.55M | $61.32M |
| Retained Earnings | ($409.71M) | ($375.83M) | ($337.58M) | ($288.76M) | ($255.75M) | ($230.97M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($24.58M) | ($33.07M) | ($47.34M) | $8.64M | ($20.87M) | ($21.62M) |
| Investing Cash Flow | ($104.0K) | ($11.0K) | ($153.0K) | ($366.0K) | ($133.0K) | ($253.0K) |
| Financing Cash Flow | ($217.0K) | $29.32M | $14.87M | $23.11M | $35.22M | $76.18M |
| CapEx | $104.0K | $11.0K | $153.0K | $366.0K | $133.0K | $253.0K |
| Free Cash Flow | ($24.68M) | ($33.08M) | ($47.49M) | $8.28M | ($21.00M) | ($21.87M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | 21.3% | - |
| Operating margin | -40274.4% | - | -64098.8% | -3311.1% | -2182.2% | - |
| EBITDA margin | -40055.6% | - | -63123.5% | -3243.2% | -2136.4% | - |
| Net margin | -37652.2% | - | -60269.1% | -3205.5% | -2165.6% | - |
| Free cash flow margin | -27426.7% | - | -58627.2% | 803.7% | -1835.6% | - |
| FCF / Net income | 0.73 | 0.87 | 0.97 | -0.25 | 0.85 | 0.98 |
| R&D / Revenue | 23471.1% | - | 47740.7% | 2246.1% | 1576.1% | - |
| SG&A / Revenue | 16903.3% | - | 16458.0% | 1165.0% | 706.0% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -65.5% | -49.7% | -59.9% | -28.9% | -30.8% | -33.5% |
| Return on equity | -432.6% | -116.7% | -134.2% | -49.7% | -33.7% | -36.2% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 |
| Quick ratio | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 |
| Cash ratio | 6.02 | 8.95 | 9.03 | 10.25 | 11.38 | 13.33 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 6.61 | 2.35 | 2.24 | 1.72 | 1.09 | 1.08 |
| Liabilities / Assets | 0.85 | 0.57 | 0.55 | 0.42 | 0.09 | 0.08 |
| Efficiency | ||||||
| Asset turnover | 0.00 | - | 0.00 | 0.01 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | -92.1% | -10.0% | - | - |
| Revenue CAGR (3y) | -55.6% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 13.9% | 18.9% | -52.2% | -36.6% | -11.5% | -1.5% |
| Net income growth (YoY) | 11.4% | 21.7% | -47.9% | -33.3% | -11.5% | -1.4% |
| EPS growth (YoY) | 14.2% | 30.6% | -52.5% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 25.4% | 30.3% | - | - | 4.0% | -1.6% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -76.1% | -10.0% | -45.3% | -9.6% | 19.9% | 986.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$90.0K totalOther Revenue$90.0K · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-8.23
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Actinium Pharmaceuticals against the 5 most active filers in the same SIC group.